T cells appear to belong to non-classical T cells with both innate and adaptive immune features. V 2V 2 (also termed V 9V 2) T cell subset exists only in primates, and in humans that represents a major T cell subpopulation in the blood. V 2V 2 T cells remain to be the only T cell subpopulation that can recognize a welldefined foreign microbial phosphoantigen. This article reviews the recent progress in our understanding immune regulation of V 2V 2 T cells.
INTRODUCTION
T cells are a minor cell population in the T cell pool. Unlike adaptive T cells, T cells have been long considered innate immune cells due to the historical absence of antigen-mediated major clonal expansion and recall immune responses in infection or re-infections. However, accumulating experience suggests that human T cells function as non-classical T cells and contribute to both innate and adaptive immune responses in infections [1, 2] . V 2V 2 (also termed V 9V 2) T cells exist only in primates, and in humans represent a major circulating Tcell subset that normally constitutes up to 65-90% of total peripheral blood T cells. Since macaque V 2V 2 T cells resemble their human counterparts, in-depth studies in nonhuman primates have been undertaken to understand biology and function of human V 2V 2 T cells. While much progress has been made to understand immune recognition of nonpeptide ligands by human
T cells, studies demonstrate that V 2V 2 T cells can undergo major clonal expansion in infections, and mount rapid recall-like expansion after mycobacterial re-infection [1] . Here, I review the recent progress in human and nonhuman primate studies for our understanding immune regulation of human T cells. I will focus on the following areas: (i) immune regulation dictating molecular interaction of V 2V 2 T cells with naturally-occurring microbial phosphoantigen; (ii) innate and adaptive features of V 2V 2 T cells in infections; (iii) unique ability of V 2V 2 T cells to traffic to and accumulate in lungs, and their effector function; (iv) V 2V 2 T effector cells and their immune regulation antagonizing CD4+CD25+Foxp3+ T regulatory cells (Treg) and Tregdriven suppression of antigen-specific T-cell immune responses.
IMMUNE REGULATION DICTATING V 2V 2 T CELL RECEPTOR INTERACTION WITH NATURALLY-OCCURRING PHOSPHOANTIGEN HMBPP

Human
T cells appear to belong to non-classical T cells with both innate and adaptive immune features [3] [4] [5] [6] . It is important to note that primate V 2V 2 T cells remain the only T-cell subset that can recognize a foreign microbial phosphoantigen. If V 2V 2 T cells contribute to adaptive immune responses and thus are not simply innate cells, one would imagine that V 2V 2 T cell receptor (TCR) binding to microbial antigen complex would be immunologically regulated by an elegant mechanism. This notion is supported by a line of evidence provided by a number of laboratories. It has been well known that V 2V 2 T cells can be activated by certain low m.w. foreign-and self-nonpeptidic phosphorylated metabolites of isoprenoid biosynthesis [e.g. (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP)] [7] [8] [9] [10] [11] commonly referred to as phosphoantigens. HMBPP is produced in the 2-C-methyl-Derythritol-4-phosphate (MEP) pathway of isoprenoid biosynthesis of most eubacteria, apicomplexan protozoa, plant chloroplasts and algae [1] . While the chemistry of phosphoantigens and their ability to activate V 2V 2 T cells have been well described, little is known about molecular mechanisms by which HMBPP interacts with T cells [12, 13] . Most studies done to date have been focused on prenyl pyrophosphates particularly IPP, but rarely the naturallyoccurring microbial phosphoantigen HMBPP [12, 14] . Earlier experiments using V 2V 2 T-cell activation as readouts demonstrated that IPP does not need to undergo cell-entry or processing and that phosphoantigen activation of V 2V 2 T cells requires cell-cell contact [12, 15] . A putative molecule, but not MHC class I, class II, CD1, appears to be required to present IPP for immune activation of V 2V 2 T cells [12] . Despite decade-long studies, however, there has been no direct evidence indicating that human or macaque V 2V 2 TCR (instead of human-macaque hybrids) can directly bind to HMBPP or HMBPP complex [16, 17] .
We presume that the development of soluble, tetrameric V 2V 2 TCR may provide a useful approach to explore the mechanism by which phosphoantigen HMBPP is associated with APC, presented and bound to V 2V 2 TCR. We therefore took advantage of our decade-long TCR expertise and MHC class I tetramer application experience [18] to develop V 2V 2 TCR tetramer. We demonstrated that soluble, recombinant V 2V 2 TCR tetramer makes it possible to visualize APC presentation of phosphoantigen HMBPP to V 2V 2 TCR [19] .
We show that exogenous HMBPP is associated with APC membrane in an appreciable affinity, and that the membrane-associated HMBPP readily bound to the V 2V 2 TCR tetramer (Fig. 1a, [19] ). The V 2V 2 TCR tetramer is shown to stably bind to HMBPP presented on membrane by various APC cell lines from humans and non-human primates but not those from mouse, rat or pig [19] . The V 2V 2 TCR tetramer also bound to the membraneassociated HMBPP on primary monocytes, B cells and T cells. Consistently, endogenous phosphoantigen produced in mycobacterium-infected DC is transported and presented on membrane, and stably bound to the V 2V 2 TCR tetramer. Interestingly, the capability of APC to present HMBPP for recognition by V 2V 2 TCR is diminished after protease treatment of APC. Thus, our studies elucidate that an affinity HMBPP-APC association confers binding to V 2V 2 TCR, and that the putative APC membrane molecule presenting HMBPP appears to be a protein or protein-associated component existing in primate APC or T cells but not rodent APC [19] . Consistent with the V 2V 2 TCR interaction with HMBPP phosphoantigen is our recent demonstration indicating nanoscale dynamic responses of V 2V 2 TCR during HMBPP-induced in vivo expansion of V 2V 2 T cells. We have innovated near-field optical microscopy (NSOM)-and fluorescent quantum dot (QD)-based nanotechnology and provided a best-optical-resolution nanoscale molecular imaging ( 50 nm) of molecules on cellsurface. We show that non-stimulating V 2V 2 TCR molecules of resting T cells are distributed individually distinct from each other on cell-surface (Fig. 1b, [20]) . Surprisingly, in vitro and in vivo HMBPP pulsation of PBMC for stimulation induces formation of V 2V 2 TCR nanoclusters. These V 2V 2 TCR nanoclusters are sustained on the membrane during an in vivo clonal expansion of V 2V 2 T cells after HMBPP/IL-2 treatment. The TCR nanoclusters can array to form nanodomains or microdomains on the membrane of clonally-expanded V 2V 2 T cells (Fig. 1b, [20] ). Interestingly, expanded V 2V 2 T cells bearing TCR nanoclusters or nanodomains were able to re-recognize phosphoantigen and to exert better effector function [20] . In contrast, non-specific stimulants cannot induce V 2V 2 TCR nanoclustering or nanodomain formation. These nanoscale dynamic findings provide further support for the hypothesis that V 2V 2 TCR recognize HMBPP-APC complex and mediate signaling for activation and expansion of V 2V 2 T cells. 
INNATE AND ADAPTIVE FEATURES OF V 2V 2 T CELLS IN INFECTIONS
Accumulating evidence suggests that V 2V 2 T cells possess both innate and adaptive immune features [21] [22] [23] [24] . The finding that "unprimed" V 2V 2 T cells can recognize and react to wide ranges of nonpeptide phospholigands with the capability of "naïve" production of cytokines has been interpreted as a pattern-recognition-like feature of innate immune cells. On the other hand, the capacity of V 2V 2 T cells to undergo major clonal expansion in primary infection and to mount rapid recall-like expansion upon re-infection has been proposed as adaptive (memory-type) immune response of these T cells [24] . Consistent with these memory-type responses is the demonstration of memory phenotypes of V 2V 2 T cells in the blood of humans [25] , long-term expansion of memory-like V 2 T cells and in vitro recall expansion of blood T cells in vaccinated or infected humans [26] [27] [28] [29] . Interestingly, while AIDS virus infection suppresses primary and recall-like expansion of V 2V 2 T cells, anti-retroviral therapy can indeed restore the capacity of V 2V 2 T cells to undergo recall-like expansion during active mycobacterial re-infection [30, 31] .
With synthetic phospholigands available for in vivo treatment, innate versus adaptive features of V 2V 2 T cells have been re-visited. While in vivo phospholigand or HMBPP treatment in combination with IL-2 has been shown to induce remarkable expansion of V 2V 2 T cells in nonhuman primates [32] [33] [34] , repeated treatments with phosphostim plus IL-2 can induce re-expansion of V 2V 2 T cells each time, but not necessarily stimulate greater magnitudes of recall expansion each time after the treatment [33] . While this finding cannot rule out the possibility that V 2V 2 T cells can contribute to adaptive immune responses in infections, it certainly suggests that V 2V 2 T cells do not exactly resemble their T cell counterpart mounting the typical recall or memory responses in response to the simple treatment comprised only of very small phospholigand molecule and IL-2. One of the explanations is that the initial phospholigand and IL-2 treatment has already reached the maximum activation/expansion potential of V 2V 2 T cells, and subsequent treatments will not be able to go beyond the saturated points.
Expansion and recall-like expansion of V 2V 2 T cells in vivo and in vitro after primary and secondary microbial infection may be driven by some other host and microbial factors, but not simply only by phosphoantigen and IL-2. Interaction or cross-talk between APC, particularly DC, and V 2V 2 T cells may confer upon these T cells some capability to undergo major expansion or recall-like expansion during infection and re-infection [35] . Moreover, some cytokines may contribute to the development of adaptive immune responses of V 2V 2 T cells in infections. This scenario is supported by the studies from us [36] and others [37] . We found that M. tuberculosis and BCG infections of macaques induced major expansion of V 2V 2 T cells and coincident expression of variant IL-4 (VIL-4) mRNA encoding a protein comprised of N-terminal 97 amino acids (a.a.) identical to IL-4, and unique C-terminal 96 a.a. including a signaling-related proline-rich motif. We then expressed and purified VIL-4 to test the possibility that this variant cytokine can contribute to major expansion of V 2V 2 T cells. The purified VIL-4 induces apparent expansion of phosphoantigen HMBPP-specific V 2V 2 T cells at dose-and time-dependent manners [36] . The unique C-terminal 96 a.a. bearing the proline-rich motif (PPPCPP) of VIL-4 appear to confer the ability to expand V 2V 2 T cells, since simultaneously produced IL-4 has only subtle effect on these T cells. Moreover, VIL-4 seems to utilize IL-4 receptor for signaling and activation, as the VIL-4-induced expansion of V 2V 2 T cells can be blocked by anti-IL-4R mAb but not anti-IL-4 mAb [36] . Surprisingly, VIL-4-expanded V 2V 2 T cells after HMBPP stimulation appear to be heterologous effector cells capable of producing IL-4, IFN-and TNF- [36] . Thus, mycobacterial infections of macaques induced variant mRNA encoding VIL-4 that functions as growth factor promoting expansion of HMBPPspecific V 2V 2 T effector cells [36] . We presume that other cytokines may also exert similar effects facilitating major expansion of V 2V 2 T cells during mycobacterial infections. In fact, it has been reported that IL-21 can also stimulate marked expansion of HMBPP-specific V 2V 2 T cells [37] .
UNIQUE ABILITY OF V 2V 2 T CELLS TO TRAFFIC AND ACCUMULATE IN LUNGS, AND THEIR EFFECTOR FUNCTION
Most pathogens invade through mucosae resulting from airborne, oral or sexual-associated transmission. Recruiting immune cells to mucosal interface or infected tissues is therefore an important defense mechanism for immune control of infection. While chemoattraction of leukocytes during inflammation has been well studied, tissue trafficking and localization of antigen-specific T cells in immune responses to infecting microbes remain understudied. Our serial in vivo studies have allowed us to address these issues. Our earlier studies demonstrated that rapid recall-like increases in numbers of V 2V 2 T cells can be seen in bronchoalveolar lavage fluid following M. tuberculosis aerosol challenge of BCG-vaccinated monkeys [1, 30] . These increases are associated with an inflammatory cell response characterized by increased numbers of neutrophils and macrophages in BAL fluid. The accumulation of V 2V 2 T cells in the lung is likely due to recruitment of these cells from the peripheral blood or lymphoid tissues, not due to local clonal expansion, after M. tuberculosis challenge. Interestingly, increases in numbers of V 2V 2 T cells are also apparent in pulmonary and intestinal mucosae in pulmonary and intestinal mucosae when an expansion of these cells is seen in the blood of monkeys inoculated intravenously with BCG [1, 30] . This increased number of V 2V 2 T cells is particularly marked in the lung despite the fact that BCG loads in the lung are undetectable or extremely low. In addition, no apparent inflammation can be seen in the pulmonary compartment following intravenous BCG inoculation. Surprisingly, greater increases in numbers of V 2V 2 T cells than T cells are evident in the lung of the monkeys intravenously inoculated with BCG [1, 30] . These results suggest that there may be a preferential migration of activated V 2V 2 T cells to the lung from the circulation or lymphoid tissues after mycobacterial infection.
More recently, we have undertaken in-depth studies to assess phosphoantigen-specific V 2V 2 T cells regarding their tissue distribution, anatomical localization, and correlation with presence or absence of TB lesions in lymphoid and nonlymphoid organs/tissues in the progression of severe pulmonary tuberculosis. Progression of pulmonary M. tuberculosis infection generate diverse distribution patterns of V 2V 2 T cells, with remarkable accumulation of these cells in lungs, bronchial lymph nodes, spleens and remote non-lymphoid organs but not in blood [38] . Increased numbers of V 2V 2 T cells in tissues are associated with M. tuberculosis infection, but independent of the severity of TB lesions [38] . In the lung with apparent TB lesions, V 2V 2 T cells are present within TB granulomas. In extrathoracic organs, V 2V 2 T cells localized in the interstitial compartment of non-lymphoid tissues, and the interstitial localization is present despite the absence of detectable TB lesions. Finally, V 2V 2 T cells accumulated in tissues appear to possess effector function of cytokine production since granzyme B is detectable in the V 2V 2 T cells present within granulomas [38] . Thus, clonally-expanded V 2V 2 T effector cells appear to undergo trans-endothelial migration, interstitial localization, and granulomatous infiltration for immune responses to M. tuberculosis infection.
To further elucidate the capacity of V 2V 2 T effector cells to traffic and accumulate in lungs and their effector functions, we have made use of HMBPP/IL-2 treatment regimen and addressed several important questions regarding trafficking and functional aspects of V 2V 2 T effector cells in mucosal interface. First, we investigated whether V 2V 2 T effector cells generated in peripheral blood and lymphoid tissues after the treatment can readily traffic to and accumulate in lungs. We demonstrated that the single-dose HMBPP plus IL-2 treatment of macaques induces a prolonged major expansion of circulating V 2V 2 T cells capable of producing perforin or IFN- (Fig. 2, [34] ). The intramuscular/subcutaneous treatment of macaques with single-dose phospholigand plus IL-2 regimen does not appear to induce detectable damage of endothelial or epithelial mucosa interface in lungs or other tissues. Therefore, any detectable increases in V 2V 2 T effector cells in the pulmonary compartment would strongly suggest that these cells traffic to and accumulate in lungs, since lungs are generally not considered lymphoid organs that can accommodate Tcell proliferation and expansion. Interestingly, HMBPP-activated V 2V 2 T effector cells after the HMBPP/ IL-2 treatment can undergo an extraordinary pulmonary accumulation, which lasts for 3-4 months although massively-expanded circulating T cells have returned to baseline levels weeks prior (Fig. 2, [34] ). Consistently, these V 2V 2 T effector cells generated in the circulation after the HMBPP/IL-2 treatment appears to traffic to oral and intestinal mucosae as well, although their accumulation in these mucosa is transient (Fig. 2, [34] ). These data provide strong evidence suggesting that V 2V 2 T effector cells can readily undergo pulmonary migration and accumulation. Second, we addressed a potential mechanism by which V 2V 2 T effector cells traffic to the pulmonary mucosa. We found that the V 2V 2 T cells that accumulate in the lung following HMBPP/IL-2 treatment display an effector memory phenotype: CCR5 + CCR7 -CD45RA -CD27 + [34] . The preferential expression of CCR5 by pulmonary V 2V 2 T cells suggests that CCR5 may contribute to recruiting HMBPP-activated V 2V 2 T cells to the lung. This scenario is indeed supported by the in vitro migration study describing a role of CCR5 and its ligands (MIP-1 , MIP-1 and RANTES) in the transendothelial migration of human V 2 T cells [39] . Further in-depth studies of transedothelial migration of V 2V 2 T cells would have to rely on development of advanced in vivo migration systems. The third question, perhaps the most important one, is whether V 2V 2 T cells that traffic to and accumulate in lungs are immunologically functional. Surprisingly, we find that most V 2V 2 T cells which migrate to the lung after HMBPP/IL-2 treatment are able to re-recognize phosphoantigen HMBPP, and produce copious amounts of IFN [34] . This is the true case even at 15 weeks after treatment [34] . Thus, these findings suggest that V 2V 2 T effector cells generated in peripheral blood or lymphoid tissues can constantly traffic to and accumulate in the pulmonary compartment, and that their antimicrobial and cytotoxic effector function may confer immunotherapeutics against infectious diseases and cancers.
V 2V 2 T EFFECTOR CELLS GENERATED AFTER HMBPP/IL-2 TREATMENT ANTAGONIZE IL-2-INDUCED TREG AND REVERSE TREG-MEDIATED SUPPRESSION OF VACCINE-ELICITED T CELLS
While many microbial and host factors can regulate human T cells, emerging evidence also suggests that T cells can also regulate other immune cells, tissue cells or pathogens [40, 41] . Recent studies have shown that human V 2V 2 T effector cells not only act as antigen presenting cells presenting MHC class I and II antigens for recognition by CD4 and CD8 T cells [42, 43] , but also promote dendritic cell maturation, and even help B cells to produce Ab [43] [44] [45] . The HMBPP-dependent cross-talk between monocytes and human T cells can drive fast inflammatory cytokine responses and monocyte differentiation to DC, and facilitate development CD4 T helper cells in the presence of additional microbial stimulants [35] . We presume that HMBPP activation of V 2V 2 T cells may also have direct impact on other T cell populations in vivo during infections or vaccination. Virtually, we have recently initiated in vivo studies to investigate the interplay between CD4+CD25+ Foxp3+ T regulatory cells (Treg) and HMBPP-activated V 2V 2 T effector cells during mycobacterial infection.
Foxp3+ Treg control immune responses to self-and foreign-antigens and play a major role in maintaining the balance between immunity and tolerance [46] [47] [48] [49] . Treg have been shown to broadly suppress activation, proliferation and/or effector functions of various immune cell populations such as conventional CD4 + and CD8 + T cells [50] , NK T cells [51] , B cells [52] , dendritic cells [53] , monocytes/ macrophages [54] , neutrophils [55] , and mast cells [56] . Depletion of CD4+CD25+ T cells induces effective antitumour immunity, enhances immune responses to invading microbes, triggers allergic responses to innocuous environmental substances [46] . However, T cell subsets capable of antagonizing Treg and their function have not been demonstrated. Development of a useful model system may help to identify potential mutual regulatory effects of Treg and other immune cells or elements. Interestingly, recent studies have shown that human recombinant IL-2 administration can lead to an increase in the frequency of circulating CD4+CD25+ regulatory T cells in cancer patients [57] [58] [59] [60] . We and others have also shown that IL-2 plus phospholigand treatment can induce remarkable expansion of V 2V 2 T cells in nonhuman primates [32] [33] [34] . We therefore took advantage of the IL-2-based in vivo model systems to assess potential interplay or mutual regulations between V 2V 2 T cells and Treg during early mycobacterial infection in nonhuman primates. 
Foxp3
+ T regulatory cells in PBMC of three groups of monkeys (BCG; BCG + IL-2; BCG + IL-2+Picostim) over time after treatment/infection. Shown are the mean values with SEM from 6 monkeys for each group. ** P < 0.01; * P < 0.05 for differences between BCG +IL-2 and BCG groups and between BCG +IL-2 and BCG +IL-2. (b) Changes in percentage and absolute numbers of V 2V 2 T cells in PBMC of three groups of monkeys (BCG; BCG + IL-2; BCG + IL-2+Picostim) over time after treatment/infection. ** P < 0.01; * P < 0.05 for differences between BCG+IL-2 and BCG groups, and between BCG+IL-2+Picostim and BCG groups or BCG+IL-2+Picostim and BCG +IL-2 groups. Note that IL-2-induced expansion of T reg (a) led to subsequent suppression of BCG-induced expansion of V 2V 2 T cells at days 21-42 (* P <0.05 for differences between BCG +IL-2 and BCG groups as well as BCG+IL-2 and BCG+IL-2+Picostim groups at days 21 and 28).
CD4
+ CD25 + Foxp3 + T cells (Fig. 3a, b, [41] ). The downregulation of IL-2-induced expansion of Treg leads to the sustained increases in numbers of V 2V 2 T cells through 42 days after the Picostim/IL-2 treatment and superimposed BCG infection. Consistently, in vitro activation of V 2V 2 T cells in PBMC by phosphoantigen+IL-2 can down-regulate IL-2-induced expansion of CD4 + CD25 + Foxp3 + T cells, but HMBPP-mediated antagonizing effect appears to require APC (monocytes) or other lymphocytes [41] . Since activated V 2V 2 T cells alone had no inhibiting effect on CD4 + CD25 + Foxp3 + T cells in the culture without APC and other cells in PBMC, we sought to determine whether some cytokines produced by phosphoantigen-activated V 2V 2 T cells contributed to the down-regulation of the IL-2-induced proliferation of T reg. We set up cytokine-neutralizing experiments in the proliferation assays using anti-IFN-, anti-IL-4, or anti-TGF-neutralizing antibodies because HMBPP phosphoantigen stimulation could up-regulate many genes including those encoding these cytokines (Wang et al, data not shown). Surprisingly, while anti-TGF-or anti-IL-4 neutralizing antibodies did not affect the HMBPP-mediated down-regulation of Treg, anti-IFN-neutralizing antibody significantly reduced the ability of HMBPP-activated V 2V 2 T cells to antagonize Treg expansion [41] . This suggests that IFN-and its network contributed to V 2V 2 T cells' antagonizing effects. Furthermore, activation of V 2V 2 T cells by Picostim+IL-2 treatment appears to reverse Treg-driven suppression of immune responses of phosphoantigen-specific IFN + or perforin+ V 2V 2 T cells and PPD-specific IFN + T cells [41] . Thus, phosphoantigen-activation of V 2V 2 T cells antagonizes IL-2-induced expansion of Treg and subsequent suppression of and anti-microbial T-cell responses in mycobacterial infections. The findings from phosphoantigen/IL-2 treatment of macaques in the context of mycobacterial infection provide the first evidence suggesting that certain T-cell subsets in the immune system can antagonize Foxp3+ Treg and their suppression of microbe-specific T-cell immune responses in infections.
In conclusion, much progress has been made for understanding immune regulation of phosphoantigenspecific human T cells. Since polyfunctional human T cells can be readily expanded by phosphoantigen/IL-2 treatment regimens, future T-cell research will elucidate mutual regulation or cross-talks between human T cells and other immune cells in the context of infection and immunity. The field is also in the position to test hypothetical broad functions of V 2V 2 T cells in infections and cancers.
